12月23日，港股高开冲高后震荡走低，午后保持低位震荡走势，截止收盘，恒生指数跌0.11%报 25774.14点，恒生科技指数跌0.69%报5488.89点，国企指数跌0.29%报8913.83点，红筹指数跌0.19%报 4067.53点。 盘面上，大型科技股走势分化，阿里巴巴涨0.55%，腾讯控股跌2.03%，京东集团涨0.45%，小米集团跌 1.51%，网易跌0.65%，美团涨0.39%，快手跌3.52%，哔哩哔哩跌0.05%；黄金股继续上涨，万国黄金集 团涨超5%，山东黄金涨超4%，招金矿业涨超2%。药捷安康跌超18%；风电股涨幅居前，东方电气涨超 8%；生物技术股走低，药捷安康跌超18%；中资券商股高开低走，东方证券跌超1%；新股诺比侃收涨 363%，轻松健康收涨158%，翰思艾泰收跌46%。 企业消息 国泰航空(00293.HK)：11月份载客253.04万人次，同比增长26%。 山高新能源(01250.HK)：附属武乡北清智慧能源与中铁十七局第二工程订立EPC合同，合同总价为人民 币4.055亿元。 中广核电力(01816.HK)：惠州1号及2号机组均处于调试阶段，预计投入运行时间分别调整为202 ...

本文源自：金融界AI电报 圣诺医药-B(02257.HK)发布公告，公司全资附属公司Sirnaomics, Inc.已完成试验药物STP707的I期试验， 并已向美国食品药品监督管理局(FDA)正式提交临床研究报告。 ...

（原标题：圣诺医药-B(02257)完成试验药物STP707的I期试验并已向FDA正式提交临床研究报告） 智通财经APP讯，圣诺医药-B(02257)发布公告，公司全资附属公司Sirnaomics, Inc.已完成试验药物 STP707的I期试验，并已向美国食品药品监督管理局(FDA)正式提交临床研究报告。 该研究纳入患有晚期、转移性或无法手术的实体瘤的成年人，该等实体瘤已经扩散或无法通过手术切 除，且其癌症对标准治疗已停止反应。STP707在该等患者中展示出确切的临床活性，部分患者疾病实 现稳定，在治疗选择有限且经过多线既往治疗的群体中延缓了疾病进展。该等患者透过静脉给药方式接 受了不同剂量的STP707。此早期阶段的结论为，STP707可以多种剂量给药，副作用大多可控。 公司相信，完成I期试验并向FDA提交临床研究报告乃STP707的一个关键里程碑。随着临床研究报告的 提交，Sirnaomics, Inc.准备在STP707 I期试验提交完成的基础上，与FDA启动讨论，以确定II期开发策 略。 ...

公司相信，完成I期试验并向FDA提交临床研究报告乃STP707的一个关键里程碑。随着临床研究报告的 提交，Sirnaomics,Inc.准备在STP707I期试验提交完成的基础上，与FDA启动讨论，以确定II期开发策 略。 圣诺医药-B(02257)发布公告，公司全资附属公司Sirnaomics,Inc.已完成试验药物STP707的I期试验，并已 向美国食品药品监督管理局(FDA)正式提交临床研究报告。 该研究纳入患有晚期、转移性或无法手术的实体瘤的成年人，该等实体瘤已经扩散或无法通过手术切 除，且其癌症对标准治疗已停止反应。STP707在该等患者中展示出确切的临床活性，部分患者疾病实 现稳定，在治疗选择有限且经过多线既往治疗的群体中延缓了疾病进展。该等患者透过静脉给药方式接 受了不同剂量的STP707。此早期阶段的结论为，STP707可以多种剂量给药，副作用大多可控。 ...

Core Viewpoint - The article discusses the significant organizational changes and strategic shifts at Huaxi Biological, particularly focusing on the recent layoffs and the company's investment in Saint Nor Pharmaceutical, indicating a transition from a "traffic empire" to a "technology engine" in the biopharmaceutical sector [3][4][5]. Group 1: Layoff Turmoil - Huaxi Biological has undergone substantial layoffs and internal investigations, with teams like "Muscle Vitality" and "Mibelle" shrinking from over a hundred to just a few members, and compensation standards set at N+1 [4][6]. - CEO Zhao Yan has initiated a "clean-up" campaign, emphasizing zero tolerance for corruption and restructuring the company's power dynamics, leading to significant turnover in the executive team [4][5]. - The layoffs have created organizational instability, risking knowledge leakage and hindering product development and market responsiveness [6]. Group 2: Shift to Small Nucleic Acids - Huaxi Biological has invested approximately HKD 139 million to acquire a 9.44% stake in Saint Nor Pharmaceutical, aiming to leverage its RNA interference technology for weight loss treatments [8][9]. - Saint Nor is recognized as the first small nucleic acid drug company listed in the Asia-Pacific region, with a robust pipeline targeting various diseases, including cancer and metabolic disorders [9][10]. - The investment is seen as a strategic move to enter the innovative drug sector, with Huaxi planning to collaborate on clinical and commercial efforts for the STP705 targeted weight loss project [11]. Group 3: The Weight Loss Drug Market - The weight loss drug market is projected to grow significantly, with estimates suggesting it could reach CNY 800-1000 billion by 2030, capturing over one-third of the global market share [13][14]. - The increasing prevalence of obesity in China, with over 200 million individuals classified as obese, presents a substantial market opportunity for weight loss solutions [13]. - Regulatory support and advancements in drug technology are expected to facilitate market entry for new weight loss drugs, enhancing the competitive landscape [12][14]. Group 4: Future Market Dynamics - The article highlights the potential for the weight loss drug market to evolve into a comprehensive metabolic management ecosystem, integrating various therapeutic approaches and technologies [16]. - By 2035, advancements in drug delivery and treatment methodologies could significantly expand the market, with the potential for annual customer value to increase from CNY 10,000 to CNY 50,000 [16]. - The narrative emphasizes the need for stakeholders to view the weight loss drug market as part of a larger metabolic revolution, rather than merely a series of individual product launches [16].

Group 1 - The stock of Sanofi Pharmaceuticals-B (02257) increased by over 17% during trading, with a current rise of 15.84% to HKD 11.85, and a trading volume of HKD 15.0443 million [1] - Sanofi Pharmaceuticals-B reported a significant decline in other income, which amounted to USD 12.4 thousand, a year-on-year decrease of 87.4%. The company recorded a loss attributable to shareholders of USD 3.698 million, which represents a year-on-year narrowing of 91% [1] - The reduction in losses is attributed to several factors, including a decrease in fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and a decrease in fair value losses on financial liabilities [1] Group 2 - Sanofi Pharmaceuticals-B's core products include STP705, STP707, and STP122G, with STP705 being the most advanced in development and expected to be the company's first commercial product by 2025 [2] - STP705 is a dual-target siRNA that simultaneously targets TGF-β1 and COX-2, and it is the first and only drug in the siRNA cancer treatment field to achieve positive Phase II clinical results. In the Phase II trial for basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [2] - The company is expanding the indications for STP705, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer. Additionally, STP705 has received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [2]

Core Viewpoint - 圣诺医药-B reported a significant reduction in losses for the six months ending June 30, 2025, compared to the same period in the previous year, despite no product sales revenue generated [1] Financial Performance - The company recorded a loss of $3.4 million for the six months ending June 30, 2025, compared to a loss of $43.5 million for the same period in 2024 [1] - The reduction in losses is attributed to decreased fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and decreased fair value losses on financial liabilities [1] Strategic Initiatives - The company is actively seeking global and regional partnerships for STP705 and STP707, evaluating collaboration opportunities for the GalAhead™ platform assets, and establishing strategic alliances to enhance development capabilities [1] - Efforts are focused on maximizing the potential of the pipeline while minimizing development risks through shared expertise and resources [1] - The company is in discussions with several venture capital funds to establish a new entity aimed at advancing its product pipeline while optimizing R&D expenditures [1] Future Outlook - The company aims to submit a New Drug Application (NDA) for STP705 as early as 2027, with commercial success dependent on positive clinical data, regulatory approval, and robust intellectual property protection [1] - The commercialization strategy includes detailed market access planning, development of necessary infrastructure, and building partnerships [1]